Barclays initiated coverage on shares of Masimo (NASDAQ:MASI) in a research report released on Friday morning, Marketbeat reports. The brokerage issued an overweight rating and a $97.00 target price on the medical equipment provider’s stock.
Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Masimo from a buy rating to a hold rating in a research note on Monday, March 5th. Piper Jaffray Companies reiterated a hold rating and set a $91.00 target price on shares of Masimo in a research report on Thursday, March 1st. Finally, BidaskClub upgraded shares of Masimo from a sell rating to a hold rating in a research report on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $101.00.
Shares of Masimo (NASDAQ:MASI) opened at $88.35 on Friday. The firm has a market cap of $4,562.07, a PE ratio of 31.33, a price-to-earnings-growth ratio of 2.32 and a beta of 0.92. Masimo has a 52 week low of $80.69 and a 52 week high of $104.71.
In other news, Director Sanford Fitch sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $93.07, for a total transaction of $186,140.00. Following the transaction, the director now directly owns 68,249 shares in the company, valued at $6,351,934.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yongsam Lee sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $88.17, for a total transaction of $881,700.00. Following the transaction, the executive vice president now owns 75,018 shares in the company, valued at $6,614,337.06. The disclosure for this sale can be found here. Insiders have sold 24,000 shares of company stock worth $2,177,340 over the last quarter. 13.10% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the company. USA Mutuals Advisors Inc. acquired a new position in shares of Masimo during the fourth quarter worth approximately $110,000. SeaCrest Wealth Management LLC acquired a new position in Masimo in the fourth quarter valued at approximately $116,000. Advisors Preferred LLC acquired a new position in Masimo in the fourth quarter valued at approximately $158,000. DekaBank Deutsche Girozentrale lifted its holdings in Masimo by 78.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock valued at $182,000 after buying an additional 925 shares during the period. Finally, MANA Advisors LLC acquired a new position in Masimo in the fourth quarter valued at approximately $227,000. Institutional investors own 82.84% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Barclays Initiates Coverage on Masimo (MASI)” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3257572/barclays-initiates-coverage-on-masimo-masi.html.
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.